Results 221 to 230 of about 23,920,837 (347)

The Impact of Time Use in Different Occupation Areas on Time Deficiency Among Mothers Depending on the Presence of Children With Disabilities. [PDF]

Occup Ther Int
Bang JH, Jang JS, Jeon BJ, Jang WH.
europepmc   +1 more source

Plant polyphenols: chemical properties, biological activities, and synthesis.

Angewandte Chemie, 2011
S. Quideau, D. Deffieux, Céline Douat-Casassus, L. Pouységu   +3 more
semanticscholar   +1 more source

Active Limb Activation [PDF]

, 2011
openaire   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Initiation and Development of Nurse Practitioner Practice in a Japanese Rehabilitation Hospital: A Mixed-Methods Descriptive Study. [PDF]

Cureus
Yamauchi R, Ohta R, Kato K, Sano C.
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Archeological data with AI- and physics-based modeling explain typhoon-induced disasters in inland China around 3000 yr B.P. [PDF]

Sci Adv
Ding K, Li S, Ding A, Lu H, Zhang J, Xi D, Huang X, Lou S, Tang X, Qiu X, He L, Ma Y, Lin H, Zhang S, Zhou D, Zhou X, Tan ZM, Fu C, Ge Q.   +18 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Respiratory Particle Emissions in Tracheostomized Outpatients: Comparable to Healthy Volunteers. [PDF]

Laryngoscope Investig Otolaryngol
Nikuri P, Matvejeff AT, Geneid A, Kinnari T, Sanmark E, Maalouf A, Pietarinen P, Sinkkonen S, Vartiainen VA.   +8 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source